Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1 - 14. (Canceled)

15. (New) Method of treatment of a disease involving a neuronal connectivity defect comprising administering to an individual in need thereof a therapeutic effective amount of one epothilone or derivative thereof.

16. (New) Method according to claim 15, wherein the disease includes a psychotic or psychiatric disorder.

17. (New) Method according to claim 15, wherein the epothilone is a compound of formula (I):



(I)

wherein:

R^1 represents H, alkyl, alkenyl or alkynyl in C_1-C_6, aryl in C_6-C_{10}, aralkyl in C_7-C_{15},

R^2, R^3 represents each H or form together C=C double bond,

R^4 represents H, C_1-C_6-alkyl in particular CH_3, fluoro substituted C_1-C_6 alkyl in particular CF_3 or CFH_2,

R^5 and R^6 form a C=C double bond or a three membered ring including O, S, NR^7, CR^8R^9 with R^7 being $C(O)R^{10}$, SO_2R^{10} and R^8, R^9, R^{10} being independently H, halogen, C_1-C_6 alkyl, C_6-C_{10} aryl, C_7-C_{15} alkaryl,

R^{11} being H, C_1-C_6 alkyl, C_6-C_{10} aryl, C_7-C_{15} alkaryl, and in particular H,

W represents $C(R^{12})$=CH, $C(R^{12})$=$C(CH_3)$, $C(R^{12})$=CF or a bicyclic aromatic/heteroaromatic radical preferably a 2-methylbenzothiazol-5-yl radical, or a 2-methylbenzoxazol-5-yl radical or a quinolin-7-yl radical, with R^{12} representing a heteroaromatic radical, preferably a 2-pyridinyl, a 2-substituted thiazol-4-yl or a 2-substituted oxazol-4-yl radical with substitution in 2-position by C_1-C_6 alkyl, pseudohalogen like CN or N_3, S-C_1-C_4-alkyl, O-C_1-C_6-alkyl, or C_1-C_6-alkyl substituted by OH, amino, halogen, pseudohalogen such as –NCO, -NCS, $-N_3$, O-(C_1-C_6)-acyl, O-(C_1-C_6)-alkyl or O-benzoyl,

X-Y represents O-C(=O), O-CH_2, CH_2-O, CH_2-C(=O),

Z represents C=O, S, S=O, SO_2,

R^{13} and R^{14} represents independently from each other H, C_1-C_6-alkyl, (CO)R^{15} or C_{1-4}-trialkylsilyl, with R^{15} being H, C_1-C_6-alkyl, fluoro substituted C_1-C_6-alkyl,

and pharmaceutically acceptable salts thereof.

18. (New) Method according to claim 15, wherein the epothilone is a derivative of following formula (II):



(II)

wherein:

R'4 represents an C_1-C_6 alkyl or substituted C_1-C_6 alkyl with substituents as F, Cl, Br or I, pseudohalogen, such as –NCO, -NCS , $-N_3$, NH_2, OH, O-(C_1-C_6)-acyl, O-(C_1-C_6)-alkyl or O-benzoyl,

R'^1 and R'^2 are independently from each other H, C_1-C_6-alkyl, $(CO)R'^5$ with R'^5 being H, C_1-C_6-alkyl, C_1-C_6-fluoroalkyl or C_{1-4}-trialkylsilyl,

R'^3 represents H, C_1-C_6-alkyl, halogen substituted C_1-C_6-alkyl, and

Y and Z form either a C=C double bond or are the O atom of an epoxide and pharmaceutically acceptable salts thereof.

19. (New) Method according to claim 18, wherein the epothilone is at least a derivative of formula (II) wherein R'^1, R'^2, R'^3 represents independently from each other, H, C_1-C_6-alkyl in particular CH_3, C_1-C_6 fluoroalkyl in particular CF_3 and Y and Z form either a C=C double bond or are together the O atom of an epoxide.

20. (New) Method according to claim 15, wherein epothilone includes at least the natural epothilone A or B of following formula:



Epothilone A



Epothilone B

or a pharmaceutically acceptable salt thereof.

21. (New) Method according to claim 15, wherein epothilone includes at least one synthetic epothilone C, D, E or F of following formula:



Epothilone C



Epothilone D



Epothilone E



Epothilone F

in particular epothilone D and pharmaceutically acceptable salts thereof.

22. (New) Method according to claim 15, wherein epothilone includes at least one synthetic epothilone of following formula:













23 (New) Method according to any claim 15, wherein the epothilone is used at a therapeutically effective amount from about 0.01/Kg/dose to about 100 mg/Kg/dose.

24. (New) Method according to claim 15, wherein the epothilone or derivative thereof is administered in pharmaceutical composition comprising at least a pharmaceutically acceptable carrier.